CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics total assets
Total assets on the balance sheet at the end of each period.
CRISPR Therapeutics's total assets was $2.65B at Jun 30, 2026. For fiscal 2025 it was $2.27B, up 1.0% from the year before. Over ten years it grew 30.4% a year on average. The highest annual figure on record is $2.75B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.27B | +1.0% |
| FY2024 | Dec 31, 2024 | $2.24B | +0.6% |
| FY2023 | Dec 31, 2023 | $2.23B | -0.6% |
| FY2022 | Dec 31, 2022 | $2.24B | -18.5% |
| FY2021 | Dec 31, 2021 | $2.75B | +50.5% |
| FY2020 | Dec 31, 2020 | $1.83B | +71.4% |
| FY2019 | Dec 31, 2019 | $1.07B | +118.1% |
| FY2018 | Dec 31, 2018 | $489.02M | +80.2% |
| FY2017 | Dec 31, 2017 | $271.35M | -21.3% |
| FY2016 | Dec 31, 2016 | $344.96M | +116.4% |
| FY2015 | Dec 31, 2015 | $159.42M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.65B | +30.6% |
| Q1 FY2026 | Mar 31, 2026 | $2.73B | +25.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.27B | +1.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.25B | -0.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.03B | -13.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.17B | -11.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.24B | +0.6% |
| Q3 FY2024 | Sep 30, 2024 | $2.26B | +8.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.34B | +6.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.44B | +8.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.23B | -0.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.09B | -11.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.20B | -10.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.24B | -13.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.24B | -18.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.35B | -16.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.46B | -15.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.61B | +33.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.75B | +50.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.82B | +90.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.90B | +177.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.96B | +94.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.83B | +71.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.49B | +106.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.05B | +111.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.01B | +102.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.07B | +118.1% |
| Q3 FY2019 | Sep 30, 2019 | $720.59M | +38.9% |
| Q2 FY2019 | Jun 30, 2019 | $494.25M | +40.0% |
| Q1 FY2019 | Mar 31, 2019 | $497.87M | +33.0% |
| Q4 FY2018 | Dec 31, 2018 | $489.02M | +80.2% |
| Q3 FY2018 | Sep 30, 2018 | $518.90M | +83.8% |
| Q2 FY2018 | Jun 30, 2018 | $353.13M | +15.8% |
| Q1 FY2018 | Mar 31, 2018 | $374.45M | +16.2% |
| Q4 FY2017 | Dec 31, 2017 | $271.35M | -21.3% |
| Q3 FY2017 | Sep 30, 2017 | $282.32M | +1.3% |
| Q2 FY2017 | Jun 30, 2017 | $304.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $322.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $344.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $278.65M | – |
See a number that looks wrong?